Charles A. Stanley MD, Founder of the Congenital Hyperinsulinism Center at CHoP, joins AmideBio’s Scientific Advisory Board

Charles A. Stanley MD joins AmideBio’s scientific advisory board to help further the Company’s soluble glucagon program for treating hyperinsulinism (HI). Dr. Stanley is a world-renowned expert on disorders of insulin regulation in children and founded the Congenital Hyperinsulinism Center at the Children’s Hospital of Philadelphia (CHoP). He helped define the various types of HI and has pioneered best practices for the diagnosis and treatment of congenital HI.

Dr. David L. Snitman joins AMIDEBIO Business Advisory Board

Dr. Snitman who is a co-founder of Array BioPharma and served as Chief Operating Officer & Vice President, Business Development from 1998 to 2015 has joined AmideBio’s business advisory board.

AMIDEBIO Closes $764,000 Equity Financing

AmideBio closed a new private placement round of $764,000 of preferred equity financing. The proceeds will be used to further the development of the Company’s pipeline of improved diabetes drug candidates, with particular focus on soluble glucagon for hyperinsulinism and glucose responsive insulin for diabetes

AMIDEBIO awarded NIH grant for hyperinsulinism program

AMIDEBIO has been awarded a $338,387 Phase 1 SBIR grant from the National Institute of Health to advance the company’s novel glucagon program for treating congenital hyperinsulinism.

AMIDEBIO granted E.U. Patent No. 2,787,083

AMIDEBIO has been granted European patent protection for novel peptide manufacturing process.

Boulder Peptide Symposium

AMIDEBIO CTO Dr. Michael Stowell will present a talk titled “Rapid-Recombinant SAR of Conformation Locked Insulin Analogs” at the 2016 Boulder Peptide Symposium Sept 26-29.

AMIDEBIO launches new website

To better serve our growing customer base AMIDEBIO has launched a new website with improved functionality and a better E-commerce experience.

ADA Meeting New Orleans

AMIDEBIO CTO Dr. Michael Stowell presented a poster at the 76th American Diabetes Association in New Orleans titled “Sparse Matrix Sampling of Anti-Fibrillation Sequence Mutations Yields a Library of Novel Solution Stable Glucagon Analogs Suitable for an Artificial Pancreas.

AMIDEBIO granted U.S. Patent No. 8,796,431

AMIDEBIO has been granted patent protection for novel peptide manufacturing process.